


# EMPA-HEART

## #AHA18



**Trial description:** Patients with type 2 diabetes mellitus (DM2) and stable CAD with or without HF were randomized in a 1:1 fashion to either empagliflozin 10 mg daily or placebo. Patients were followed for 6 months.



### RESULTS

- Primary endpoint, change in LV mass index, empagliflozin vs. placebo: -2.6 vs. -0.01 g/m<sup>2</sup>, p = 0.01
- Change in systolic BP: -7.9 vs. -0.7 mm Hg, p = 0.003
- Change in LV end-systolic volume index : -1.0 vs. 0.04 ml/m<sup>2</sup>, p = 0.36, change in LVEF: 2.2% vs. -0.01%, p = 0.07

### CONCLUSIONS

- Empagliflozin results in salutary effects on LV remodeling at 6 months among patients with DM2 and stable CAD but normal EF and without a clear history of HF (only 6% had known HF in this trial)

Presented by Dr. Subodh Verma at AHA 2018